Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies

Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat cholangiocarcinoma. A compartmental population pharmacokinetics model was developed using data from 318 patients with cancer enrolled in a phase 1 dose‐escalation/dose‐expansion study, a phase 1 Japanese PK bridging study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Tao, Chen, Xuejun, Liu, Xiang, Yeleswaram, Swamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306536/
https://www.ncbi.nlm.nih.gov/pubmed/35092702
http://dx.doi.org/10.1002/cpdd.1038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306536/
https://www.ncbi.nlm.nih.gov/pubmed/35092702
http://dx.doi.org/10.1002/cpdd.1038

Ejemplares similares